Cardiovascular Engineering and Technology

Cardiovascular Engineering and Technology is the bimonthly journal of the Biomedical Engineering Society, published by Springer, and since 2010 it has carried engineering work on the heart and the circulation. Its 2025 Journal Impact Factor is 2.4.《心血管工程与技术》是美国生物医学工程学会（Biomedical Engineering Society）的会刊，由 Springer 出版，2010 年创刊，双月刊，刊载以工程原理研究心脏与循环系统的工作，2025 年期刊影响因子为 2.4。

Scope

• The aims statement describes a wide spectrum of research, basic to translational, and covers all aspects of cardiovascular physiology and medical treatment, with no branch of the field excluded in advance.宗旨声明把收稿范围写成从基础到转化的宽谱系，覆盖心血管生理与医学治疗的各个方面，没有哪一分支被预先排除。
• It offers academic and industrial investigators a forum for work that uses engineering principles and methods to advance fundamental knowledge and technological solutions for the cardiovascular system.刊物为学术界与产业界研究者提供一个论坛，刊登运用工程原理与方法推进心血管系统基础知识与技术方案的稿件。
• Manuscripts are invited across scales, from subcellular events up to whole-system behaviour, and the list of topics that follows is illustrative rather than closed.征稿横跨各个尺度，从亚细胞过程一直到整体系统的行为，随后的选题清单只作示例，并未封闭。
• Implantable medical devices head the topic list, a slot that takes in ventricular assist systems, prosthetic valves, stents and the controllers that drive them.植入式医疗器械排在清单首位，心室辅助系统、人工瓣膜与支架一类装置都在其中。
• Hemodynamics and tissue biomechanics follow, pairing flow measurement and simulation with the mechanical behaviour of vessel walls, myocardium and valve leaflets under load.血流动力学与组织生物力学紧随其后，把流动的测量与仿真同血管壁、心肌与瓣叶在载荷下的力学行为放在一起。
• Functional imaging forms a third strand, read here as a route to quantifying flow, perfusion and deformation inside the beating heart rather than as a purely diagnostic service.功能成像构成第三条线索，刊物把它看作量化搏动心脏内血流、灌注与形变的途径，而不只是诊断服务。
• Surgical devices and electrophysiology sit in the same list, one drawn from the operating theatre and the other from mapping and ablation in the catheter laboratory.外科器械与电生理同在这一清单里，前者取自手术台，后者关乎导管室里的标测与消融。
• Tissue engineering and regenerative medicine are named as well, beside diagnostic instruments, the transport and delivery of biologics, and sensors of every kind.组织工程与再生医学同样在列，诊断仪器、生物制品的输运与递送以及各类传感器也一并收入。
• Reviews and state-of-the-art surveys of these topics are solicited on the same footing as reports of original research, so a synthesis paper is welcome at any time.这些选题的综述与现状评述和原创新研究报告处在同等征集之列，综合性的稿件随时可以投来。
• Ten article types are open, among them the original article, the review, the short communication, the methods paper, the commentary, the opinion paper and the letter to the editor.可投的稿件类型共 10 类，原创论文、综述、短通讯、方法论文、评论、观点文章与致编辑信都在其中。
• Length limits run to 6,000 words for regular articles, 8,000 for reviews and 2,000 for short communications, each figure counted with the abstract and the references included.篇幅上限为常规论文 6000 词，综述 8000 词，短通讯 2000 词，三个额度都把摘要与参考文献计算在内。
• Abstracts are structured at 150 to 250 words and carry four labelled parts, purpose, methods, results and conclusions, a format applied to reports of original research.摘要为结构式，长度 150 至 250 词，分目的、方法、结果与结论四个标注段落，这一格式用于原创研究报告。
• Four to six keywords are required with every manuscript, and the guidelines fix that count without exception for any of the article types.每篇稿件须附 4 至 6 个关键词，指南对这一数量不设任何稿件类型的例外。
• Under the type 1 research data policy, authors are encouraged to deposit the data behind their results in a public repository and to say where it can be found.刊物执行第一类研究数据政策，鼓励作者把支撑研究结果的数据存入公共仓库，并注明数据的位置。
• No page charges are levied, online and print colour images carry no fee, and the hybrid model leaves the subscription route free to authors.刊物不收版面费，在线与纸本彩图均不收费，混合出版模式让走订阅路线的作者不承担费用。

History

• The first issue appeared on 17 February 2010 as Volume 1, Issue 1, and the opening papers included a tribute to Leslie A. Geddes, a pioneer of biomedical engineering.第 1 卷第 1 期于 2010 年 2 月 17 日出版，开卷几篇文章中有一篇纪念生物医学工程先驱 Leslie A. Geddes。
• The title was set up as the journal of the Biomedical Engineering Society, which holds the copyright, while Springer took on publication and the imprint was placed in New York.刊物按美国生物医学工程学会（Biomedical Engineering Society）会刊设立，著作权归学会所有，出版事务由 Springer 承担，出版地登记在纽约。
• One volume has appeared each year since then, six issues to a volume, and the 2026 volume is the seventeenth.此后每年出版一卷，每卷 6 期，2026 年的这一卷为第 17 卷。
• Volumes 14 to 16, covering 2023 to 2025, each ran to six numbers dated February, April, June, August, October and December, and Volume 17 has reached its fourth issue.第 14 至 16 卷对应 2023 至 2025 年，各出 6 期，月份落在 2 月、4 月、6 月、8 月、10 月与 12 月，第 17 卷已出到第 4 期。
• The print ISSN is 1869-408X and the electronic ISSN 1869-4098, so the two versions are catalogued apart in library records.印刷版 ISSN 为 1869-408X，电子版 eISSN 为 1869-4098，两个版本在图书馆目录中分别著录。
• MEDLINE took the title from Volume 6, Issue 1 in March 2015, and PubMed had carried selected citations only before that point.MEDLINE 自 2015 年 3 月的第 6 卷第 1 期起收录本刊，此前 PubMed 只做选择性摘录。
• A special issue in Volume 12, Issue 6 of 2021 marked the fortieth anniversary of Ajit Yoganathan's research laboratory, under the heading Shaping the Field of Cardiovascular Fluid Mechanics.2021 年第 12 卷第 6 期出一期专辑，题为 Shaping the Field of Cardiovascular Fluid Mechanics，纪念 Ajit Yoganathan 实验室成立四十周年。
• Publishing follows a hybrid model as well, 153 articles have appeared in open access so far, and gold open access accounted for 35.06 per cent of the 2025 output.出版同样采混合模式，累计已有 153 篇文章以开放获取方式刊出，2025 年统计中金色开放获取占 35.06%。
• The Journal Impact Factor has moved from 2.305 in 2022 to 1.6 in 2023, 1.8 in 2024 and 2.4 in 2025, with the five-year figure also at 2.4.影响因子从 2022 年的 2.305 降到 2023 年的 1.6，2024 年为 1.8，2025 年回到 2.4，五年影响因子同为 2.4。
• In the 2025 Journal Citation Reports the title is placed 117 of 237 in cardiac and cardiovascular systems, second quartile, and 81 of 130 in biomedical engineering, third quartile.2025 年的期刊引证报告把它排在心血管系统类 117/237，属第二四分位，生物医学工程类排 81/130，属第三四分位。
• Speed and reach are reported on the journal home page, a median of 28 days from submission to first decision and 188.2k downloads across 2025.刊页公布处理速度与阅读规模，投稿到首次决定的中位时间为 28 天，2025 年下载量为 18.82 万次。
• About 41 papers appear each year, the citation base stands near 1,330 and the cited half-life is 5.5 years, so the literature stays in use long after publication.每年发文约 41 篇，总被引接近 1330 次，被引半衰期 5.5 年，这批文献在发表多年之后仍被引用。
• Abstracting and indexing take in Science Citation Index Expanded, Medline, Scopus, EI Compendex, EMBASE and INSPEC, with ProQuest and EBSCO searching it and CLOCKSS and Portico archiving it.收录范围含 SCIE 与 Medline，也列入 Scopus、EI Compendex、EMBASE 与 INSPEC，ProQuest 与 EBSCO 提供检索，CLOCKSS 与 Portico 负责长期保存。
• The 2025 record also carries a Journal Citation Indicator of 0.47, with a percentile of 50.8 that places the title mid-field among cardiac journals.2025 年的记录另给出 0.47 的期刊引文指标，百分位为 50.8，在心脏病学刊物中处于中段。

Editors

• Keefe Manning of the Department of Biomedical Engineering at Pennsylvania State University, University Park, is Editor-in-Chief.主编为 Keefe Manning，任职于大学公园的宾夕法尼亚州立大学（Pennsylvania State University）生物医学工程系。
• Zhenglun (Alan) Wei of Worcester Polytechnic Institute serves as Deputy Editor-in-Chief, the second name on the masthead.副主编为伍斯特理工学院（Worcester Polytechnic Institute）的 Zhenglun (Alan) Wei，在编委名单中列名第二。
• Two senior editorial consultants sit above the associate editors, Shu Chien of the University of California San Diego and Ajit P. Yoganathan of Georgia Institute of Technology.高级编辑顾问两位，分别是加州大学圣迭戈分校（University of California San Diego）的 Shu Chien 与佐治亚理工学院（Georgia Institute of Technology）的 Ajit P. Yoganathan。
• Some 55 associate editors handle manuscripts, drawn from universities, children's hospitals, medical device firms and regulatory agencies across North America, Europe and Asia.约 55 位副编辑分担稿件处理，来源包括高校、儿童医院、医疗器械企业与监管机构，分布在北美、欧洲与亚洲。
• Associate editors from United States universities include Alison Marsden at Stanford, Michael S. Sacks at Texas at Austin and Christine P. Hendon at Columbia.美国高校一侧的副编辑包括斯坦福大学的 Alison Marsden、得克萨斯大学奥斯汀分校的 Michael S. Sacks 与哥伦比亚大学的 Christine P. Hendon。
• Clinical work comes through Pedro del Nido at Boston Children's Hospital and Harvard Medical School, Mark A. Fogel at the Children's Hospital of Philadelphia and Kerem Pekkan at Nationwide Children's Hospital.临床一侧由波士顿儿童医院与哈佛医学院的 Pedro del Nido 承担，费城儿童医院的 Mark A. Fogel 与全国儿童医院的 Kerem Pekkan 同样在册。
• Industry and regulation appear through Sal Marquez of Edwards Lifesciences, Scott C. Corbett of Abiomed and Changfu Wu of the US Food and Drug Administration.产业与监管一侧有 Edwards Lifesciences 的 Sal Marquez，Abiomed 的 Scott C. Corbett，以及美国食品药品监督管理局（US Food and Drug Administration）的 Changfu Wu。
• Europe and Asia are covered by Patrick Segers at Ghent, Francesco Migliavacca at Politecnico di Milano, Yun Xu at Imperial College London and Hwa Liang Leo at the National University of Singapore.欧洲与亚洲有根特大学的 Patrick Segers，米兰理工大学的 Francesco Migliavacca，伦敦帝国理工学院的 Yun Xu，以及新加坡国立大学的 Hwa Liang Leo。
• Review is single-blind, so referees know who wrote the paper while authors do not learn who reviewed it.评审采单盲制，审稿人知道作者是谁，作者不会得知审稿人身份。
• An editor screens each submission first, an associate editor then invites the anonymous referees, and only the Editor-in-Chief can make the final decision.每篇稿件先由编辑初评，再由副编辑邀请匿名审稿人，最终决定只能由主编作出。
• Guest-edited special issues pass through the same sequence, and a guest editor who submits to their own collection is kept out of its handling.客座编辑主持的专辑走同一套流程，客座编辑若向自己的专辑投稿，则回避该稿的处理。
• Manuscripts go through Editorial Manager, and the guidelines ask for a Word document or a LaTeX source plus a statement of any generative AI use, with accountability left to the authors.稿件经 Editorial Manager 提交，指南要求提供 Word 文档或 LaTeX 源文件，并声明是否使用生成式人工智能，责任由作者承担。